References
1. Rivera-Luna R,
Shalkow-Klincovstein J, Velasco-Hidalgo L, et al. Descriptive
Epidemiology in Mexican children with cancer under an open national
public health insurance program. BMC Cancer . 2014;14:790.
Published 2014 Oct 29. doi:10.1186/1471-2407-14-790
2. Reyes-León A, Juárez-Velázquez R, Medrano-Hernández A, et al.
Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse
and Death in Mexican Children with Acute Lymphoblastic Leukemia. PLoS
One. 2015;10(7):e0130756. Published 2015 Jul 1.
doi:10.1371/journal.pone.0130756
3. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet.
2020;395(10230):1146-1162. doi:10.1016/S0140-6736(19)33018-1
4. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the
clonal origins of relapsed acute lymphoblastic leukemia. Science.
2008;322(5906):1377-1380. doi:10.1126/science.1164266
5. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in
paediatric acute lymphoblastic leukaemia. Lancet Oncol.
2008;9(9):873-883. doi:10.1016/S1470-2045(08)70229-8
6. Inaba H, Pui CH. Immunotherapy in pediatric acute lymphoblastic
leukemia. Cancer Metastasis Rev. 2019;38(4):595-610.
doi:10.1007/s10555-019-09834-0
7. Yu J, Wang W, Huang H. Efficacy and safety of bispecific T-cell
engager (BiTE) antibody blinatumomab for the treatment of
relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s
lymphoma: a systemic review and meta-analysis. Hematology.
2019;24(1):199-207. doi:10.1080/16078454.2018.1549802
8. Maloney KW, Gore L. Agents in Development for Childhood Acute
Lymphoblastic Leukemia. Pediatric Drugs. 2017;20(2):111-120.
doi:10.1007/s40272-017-0268-7
9. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in
paediatric acute lymphoblastic leukaemia. Lancet Oncol.
2008;9(9):873-883. doi:10.1016/S1470-2045(08)70229-8
10. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and
auto-SCT for haematological diseases, solid tumours and immune
disorders: current practice in Europe, 2015. Bone Marrow Transplant.
2015;50(8):1037-1056. doi:10.1038/bmt.2015.6
11. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat
relapsed childhood acute lymphoblastic leukemia. Blood.
2012;120(14):2807-2816. doi:10.1182/blood-2012-02-265884
12. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment
of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2606-2621.
doi:10.1080/10428194.2019.1605071
13. August KJ, Guest EM, Lewing K, Hays JA, Gamis AS. Treatment of
children with relapsed and refractory acute lymphoblastic leukemia with
mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Pediatr Blood Cancer. 2020;67(3):e28062. doi:10.1002/pbc.28062
14. Mustafa O, Abdalla K, AlAzmi AA, Elimam N, Abrar MB, Jastaniah W.
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute
leukemia in the era of targeted novel therapies. J Oncol Pharm Pract.
2019;25(8):1831-1838. doi:10.1177/1078155218817816
15. Keating AK, Gossai N, Phillips CL, et al. Reducing minimal residual
disease with blinatumomab prior to HCT for pediatric patients with acute
lymphoblastic leukemia. Blood Adv . 2019;3(13):1926-1929.
doi:10.1182/bloodadvances.2018025726
16. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for
Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines
from the American Society for Blood and Marrow Transplantation. Biol
Blood Marrow Transplant. 2015;21(11):1863-1869.
doi:10.1016/j.bbmt.2015.07.032
17. Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy
Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival
in Children, Adolescents, and Young Adults With First Relapse of B-Cell
Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA.
2021;325(9):833-842. doi:10.1001/jama.2021.0669
18. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic
leukaemia. Lancet Oncol. 2013;14(6):e205-e217.
doi:10.1016/S1470-2045(12)70580-6
19. Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood
acute lymphoblastic leukemia is independent of initial treatment
intensity: a report from the Children’s Oncology Group. Blood.
2011;117(11):3010-3015. doi:10.1182/blood-2010-07-294678.